Jpmorgan Chase & CO Achilles Therapeutics PLC Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Achilles Therapeutics PLC stock. As of the latest transaction made, Jpmorgan Chase & CO holds 137 shares of ACHL stock, worth $141. This represents 0.0% of its overall portfolio holdings.
Number of Shares
137
Previous 137
-0.0%
Holding current value
$141
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding ACHL
# of Institutions
24Shares Held
24.3MCall Options Held
0Put Options Held
0-
Syncona Portfolio LTD Guernsey, Channel Islands, X011.1MShares$11.4 Million14.01% of portfolio
-
Bml Capital Management, LLC Zionsville, IN4.1MShares$4.22 Million2.46% of portfolio
-
Fcpm Iii Services B.V. Naarden, P72.39MShares$2.46 Million0.42% of portfolio
-
Redmile Group, LLC San Francisco, CA1.61MShares$1.66 Million0.11% of portfolio
-
Vestal Point Capital, LP New York, NY1.5MShares$1.55 Million0.12% of portfolio
About Achilles Therapeutics plc
- Ticker ACHL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,774,000
- Market Cap $42M
- Description
- Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in ...